Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|July 1, 2001
Supplements and Featured Publications
- New Developments in the Treatment of Irritable Bowel Syndrome
- Volume 7
- Issue 8 Suppl
Continuing Medical Education Quiz
Advertisement
Articles in this issue
over 25 years ago
Participating Facultyover 25 years ago
Introductionover 25 years ago
Defining and Diagnosing Irritable Bowel Syndromeover 25 years ago
Drug Therapy Options for Patients with Irritable Bowel Syndromeover 25 years ago
Selected AbstractsAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Pulmonary Embolism Can Affect Elite Athletes, Too: Samantha Pettigrew, MD
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
UPMC Health Plan's Food as Medicine Pilot for Members With Diabetes
5